SynthesisDigestive diseases and sciences2026
Systematic Review of Bile Acids Metabolism in Crohn's Disease: Implications for Pathogenesis and Therapeutic Interventions.
Synthesis in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pre-transplant Colonoscopy: Safety Reassured, Questions Remain.Digestive diseases and sciences · 2026Article
- Metabolomic Profiling of Fecal Samples Reveals Distinct Signatures Associated with Disease Phenotypes and Locations in Crohn's Disease.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCrohn's disease (CD) is a chronic inflammatory bowel disorder characterized by transmural inflammation of the gastrointestinal tract. This systematic review aims to unravel the intricate relationship between CD and bile acids (BA), exploring variations and inconsistencies in BA composition related to disease activity, anatomical localization, and surgical history.
methodsStudies reporting BA in CD from PubMed, Scopus, Embase, Cochrane, and WOS have been collected. Data extraction encompassed various study characteristics, population demographics, and BA measurements in serum, intestinal, and fecal compartments. Quality assessment was performed using appropriate tools for different study designs.
resultsTwenty-five studies met the inclusion criteria, comprising 656 patients with CD and 339 healthy controls. Secondary BA-deoxycholic acid and lithocholic acid (LCA)-were consistently reduced in patients with CD, particularly in active disease and following ileal resection. Total serum BA levels showed no significant differences between CD and controls, though conjugated primary BA (cholic acid [CA] and chenodeoxycholic acid [CDCA]) were variably decreased postprandially. Intestinal BA pool size was reduced in ileal and ileocolonic CD, while fecal BA excretion was elevated, especially in patients with ileal resection. Gallbladder bile in CD demonstrated reduced secondary BA fractions and undetectable LCA.
conclusionCrohn's disease is associated with significant disturbances in BA metabolism, particularly a reduction in secondary BA and increased fecal excretion, which were mainly due to ileal dysfunction, microbial dysbiosis, and accelerated transit. These alterations may contribute to disease pathogenesis and offer potential as diagnostic biomarkers or therapeutic targets based on BA dynamics.
Indexed as
Identifiers
41225190What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.